NEWARK, Del: , Oct. 20, 2022 (GLOBE NEWSWIRE) -- The global companion animal specialty drugs market is anticipated to reach a valuation of US$ 56,828.56 Mn by 2032, with the market growing at an average CAGR of 4.21% from 2022 to 2032. Currently valued at US$ 37,624.67 Mn, the companion animal specialty drugs market is driven by the growing adoption of pets and the rising focus on animal health. The rise in the number of animal-derived products will further aid the growth of the companion animal specialty drugs market during the forecast period.
In the past few years, there’s been a rise in the number of pet owners as well as a growing awareness regarding the health of pet animals. In addition to this, technological advances in the administration of novel veterinary medicines will likely supplement the growth of the companion animal specialty drugs market through the assessment period. Again, the manufacture and approval of new drugs for the treatment of various animal ailments is stimulating the demand for companion animal specialty drugs. For instance, the growing occurrence of obesity amongst pet dogs and other companion animals contributes to a surge in the sales of anti-obesity drugs.
Get more Insights by Downloading Report Sample@ https://www.futuremarketinsights.com/reports/sample/rep-gb-3984
Moreover, the significant rise in the number of animal healthcare and NGOs in the past couple of years is one of the major growth drivers of the companion animal specialty drugs market. Also, some pet diseases can even lead to serious effects on humans and need to be mitigated so as to deter infection. All of these factors contribute to the growth of the target market during the forecast period.
“Surge in the introduction of new veterinary medicines, rise in the number of pet owners, and growing awareness of animal health are furling the global growth of the companion animal specialty drugs market over the forecast period,” says an FMI analyst.
Key Takeaways:
- Surging number of animal healthcare centers and NGOs will strengthen the market prospects.
- The companion animal specialty drugs market in the U.S. will account for 88% of the North American market share.
- Brazil’s companion animal specialty drugs market will be valued at US$ 426 Mn in 2022.
- The companion animal specialty drugs market in Germany will expand at a CAGR of 2.4%.
- Online veterinary pharmacies will grow at a CAGR of 6.8%.
- The parasiticide drug segment accounted for a market share of 32.2% in
- By product type, the vaccines segment will reach a value of US$ 2.89 Bn in 2022.
- By route of administration, the oral segment will account for a value of US$ 2.86 Bn in 2022.
Use promo code ->> FMITODAY to get flat 20% discount
Competitive Landscape
Merck Animal Health (Merck & Co., Inc.), Boehringer Ingelheim International GmbH., Elanco Animal Health Incorporated, Virbac S.A., Biogenesis Bago SA, Piramal Group, Zoetis, NEOGEN Corporation., Vetoquinol S.A., and Ceva Santé Animale among others are some of the major players in the companion animal specialty drugs market profiled in the full version of the report.
Leading market players are focusing on developing innovative products with fewer side effects. These organizations are also adopting tactics like product releases, partnerships, collaborations, and other inorganic strategies to expand their consumer base.
More Insights into Companion Animal Specialty Drugs Market Report
In its latest report, FMI offers an unbiased analysis of the global companion animal specialty drugs market, providing historical data and forecast statistics for 2022 to 2032. To understand the global market potential, growth, and scope, the market is segmented on the basis of product type (antibiotics, anti-inflammatory drugs, parasiticides, heartworm, behavioral products, nutritional products, anti-obesity drugs, skin care products, vaccines), distribution channel (modern trade, online distribution, neighborhood stores, other retail formats), and region.
Ask your Queries to Analyst@ https://www.futuremarketinsights.com/ask-question/rep-gb-3984
According to the latest FMI reports, based on segmentation, the vaccines segment is anticipated to dominate the market with a value of about US$ 2.89 Bn in 2022. On the basis of the distribution channel, online veterinary pharmacies will likely account for 37.8% of the market share while expanding at a CAGR of 6.8% during the forecast period.
Based on region, the companion animal specialty drugs market in the United States will likely account for 88% of the revenue share in North America. The growing adoption of pets coupled with many pet owners interested in taking better care of their pets fuels the growth of the companion animal specialty drugs market in this country. Brazil and Germany are two other countries that are expected to register considerable growth in the companion animal specialty drugs market during the forecast period.
Key Segments in the Companion Animal Specialty Drugs Market
By Product:
- Antibiotics
- Anti-Inflammatory Drugs
- Parasiticides
- Heartworm
- Behavioral Products
- Nutritional Products
- Anti-Obesity Drugs
- Skin Care Products
- Vaccines
By Distribution Channel:
- Modern Trade
- Online Distribution
- Neighborhood Stores
- Other Retail Format
Request Customization @ https://www.futuremarketinsights.com/customization-available/rep-gb-3984
Table of Content
1. Executive Summary
2. Market Introduction
2.1. Market Definition
2.2. Market Taxonomy
3. Global Companion Animal Drugs Market Analysis Scenario
3.1. 3.2. Market Size (US$ Mn) and Forecast
3.1.1. 3.2.1. Market Size and Y-o-Y Growth
4. Market Dynamics
4.1. Drivers
4.2. Restraints
4.3. Opportunity
4.4. Global Trends
4.5. PEST Analysis - U.S.
4.6. PEST Analysis - Europe
4.7. Portor's Five Analysis
Toc to be Continued…
Explore FMI’s Extensive Coverage in Healthcare Domain:
Injectable Drugs Market Growth: The global injectable drugs market is expected to reach US$ 531.8 Bn in 2022. Sales in the market will increase at a CAGR of 5.8%, reaching US$ 937.0 Bn by 2032.
Antimetabolite Drugs Market Share: Expanding at a CAGR of 1.8%, the global Antimetabolite Drugs market is projected to increase from a valuation of US$ 5,504.3 Mn in 2021 to US$ 6,579.2 Mn by 2032
DNA Synthesis Market Analysis: The DNA synthesis market is projected at a CAGR of 7.7% during the forecast period. The market is likely to be valued at US$ 261.9 Mn in 2022 and at US$ 592.1 Mn by 2032.
Knee Reconstruction Devices Market Size: The global knee reconstruction devices market is expected to reach a market valuation of US$ 8.28 Billion by the year 2022, accelerating with a moderate CAGR of 4.3% by 2022-2032.
Electric Acupuncture Devices Market Forecast: Global electric acupuncture devices market demand is anticipated to be valued at US$ 12.9 Million in 2022, forecast a CAGR of 7.2% to be valued at US$ 27.8 Million from 2022 to 2032.
About Future Market Insights, Inc.
Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
